Pneumologie

Real-life omalizumab exposure and discontinuation

Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of pediatric and adult asthmatics

INTRODUCTION

This real-life study aimed to assess omalizumab treatment patterns in adult and pediatric asthma patients, and to describe asthma control and healthcare resource use (HCRU) at omalizumab initiation and discontinuation.

The French Healthcare Database System (SNDS) was used to identify asthma patients aged ≥6 years who initiated omalizumab for at least 16 weeks from 2009 to 2019. We examined omalizumab treatment patterns using dispensation records..

find the whole article here ==>doi: 10.1183/13993003.03130-2021

Authors
Humbert M, Bourdin A, Taillé C, Kamar D, Thonnelier C, Lajoinie A, Rigault A, Deschildre A, Molimard M.

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Persistence and Patterns of Exposure to Omalizumab
Pneumologie

Persistence and Patterns of Exposure to Omalizumab

Economic Burden of Severe Asthma With Omalizumab
Pneumologie

Economic Burden of Severe Asthma With Omalizumab

Schémas d’exposition à l’omalizumab
Pneumologie

Schémas d’exposition à l’omalizumab